Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Titel:
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Auteur:
Kristeleit, Rebecca Lisyanskaya, Alla Fedenko, Alexander Dvorkin, Mikhail de Melo, Andreia Cristina Shparyk, Yaroslav Rakhmatullina, Irina Bondarenko, Igor Colombo, Nicoletta Svintsitskiy, Valentyn Biela, Luciano Nechaeva, Marina Lorusso, Domenica Scambia, Giovanni Cibula, David Póka, Róbert Oaknin, Ana Safra, Tamar Mackowiak-Matejczyk, Beata Ma, Ling Thomas, Daleen Lin, Kevin K McLachlan, Karen Goble, Sandra Oza, Amit M